Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

BioRestorative Therapies Inc
Healthcare
P/NCAV
0.55x
Ticker
BRTX
Exchange
NASDAQ
Country
United States
Close
1.34 $
Mkt Cap
5.7M $
EV
4.8M $
NCAV Burn Rate
28.9%
Current Ratio
10.72
Debt/Equity
0.0
EV/REV
32.7x
EV/EBIT
-0.3x
EV/FCF
-0.8x
Dilution
186.7% p.A
Total Net Income
-147.2M $
Cheapness
8.0%
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person-s own) cultured mesenchymal stem cells collected from the patient-s bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average